BioTechX Basel – Focus on biotechnology and genomics

BioTechX in Basel is a conference and trade fair for biotechnology and genomics aimed at a specialist audience from research, industry and clinical practice. In Basel, one of Europe's most important life science locations, scientists, data analysts, pharmaceutical companies and technology providers come together to discuss current developments in molecular research and data-driven medicine. The focus is on combining experimental biotechnology with modern methods of genomics and bioinformatics. With its high density of pharmaceutical companies, start-ups and university institutions, Basel offers an environment that is particularly suitable for such an event. The region has been decades. Accordingly, BioTechX has high professional standards, clearly distinguishing itself from public-oriented trade fairs and focusing on scientific depth.

Biotechnology between laboratory and application

Biotechnology is a collective term for processes in which biological systems are used for technical purposes. In Basel, the spectrum of topics ranges from recombinant DNA technology and cell therapies to biopharmaceutical production. Both basic research and regulatory and industrial aspects are discussed. The focus is on questions such as:

• How can genetic information be analysed more precisely?
• What role do automated laboratory processes play?
• How can biotechnological processes be scaled?
• What regulatory framework applies to new therapies?

BioTechX combines scientific presentations with practical case studies. Companies present platform technologies, while research institutions provide insights into ongoing projects. This highlights the fact that biotechnology today is highly interdisciplinary. Computer science, statistics and machine learning are just as relevant as classical molecular biology.

Genomics and data-driven medicine

A central focus of BioTechX is genomics. Advances in sequencing technology have accelerated the analysis of entire genomes and made it more cost-effective. This opens up new perspectives for personalised medicine, oncology and rare diseases. Topics discussed include:

• Next-generation sequencing quencing and single-cell analysis
• Genome-wide association studies
• CRISPR-based gene editing
• Data integration and bioinformatics

Processing large amounts of data poses considerable challenges for research and industry. High-performance computers, cloud infrastructures and specialised software solutions have become indispensable. In Basel, developers of such systems meet with users from clinics and research. The exchange between these groups is a central element of the event.

Interface between the pharmaceutical industry and start-ups

Basel is considered a global hub for the pharmaceutical industry. International corporations have their headquarters or major research centres here. At the same time, a dynamic environment for young biotechnology companies is emerging. BioTechX acts as an interface between established players and innovative start-ups. Investors, venture capitalists and strategic partners use the event to identify new technologies. Presentations by young companies provide insight into innovative approaches, for example in the field of cell and gene therapy or AI-supported drug discovery. Cooperation between industry and academic research is increasingly seen as a prerequisite for successful product development.

Regulation, ethics and social dimension

Biotechnology and genomics also raise ethical and regulatory questions. The modification of genetic information, especially in the human context, is a socially sensitive issue. In Basel, therefore, not only technical aspects are discussed, but also legal frameworks and ethical guidelines. Regulatory requirements for clinical trials, data protection for genetic data and international harmonisation of standards are recurring themes. Representatives from government agencies, industry and academia are looking for solutions that enable innovation while ensuring safety. BioTechX makes it clear that technological advances must always be considered in the context of social responsibility. Transparency towards the public and politicians is crucial, especially in the field of genomics.

Basel as a life science ecosystem

Basel offers ideal conditions for a trade fair with this profile. Its proximity to leading universities, research institutions and global companies creates a dense network. The city's international orientation makes it easy for participants from Europe, North America and Asia to travel there. In addition to the technical dimension, the location also plays a strategic role. The concentration of expertise, capital and infrastructure makes Basel a hub for bioscientific innovation. BioTechX reflects this ecosystem by bringing together different players in one place. Biotechnology and genomics are developing rapidly. New sequencing methods, data-driven analysis techniques and therapeutic approaches are bringing about lasting change in medical practice. This change is particularly evident in Basel. BioTechX thus represents a format that combines scientific depth, industrial application and regulatory discussion.

Further information can be found on the organiser's website: www.terrapinn.com